Cytoplasmic Trop-1/Ep-CAM overexpression is associated with a favorable outcome in node-positive breast cancer

Japanese Journal of Clinical Oncology

Volumn 42, Issue 12, 2012, Pages 1128-1137

  Alberti, Saverio ^a   Ambrogi, Federico ^b   Boracchi, Patrizia ^b   Fornili, Marco ^b   Querzoli, Patrizia ^c   Pedriali, Massimo ^c   La sorda, Rossana ^a   Lattanzio, Rossano ^a   Tripaldi, Romina ^a   Piantelli, Mauro ^a   Biganzoli, Elia ^b,d   Coradini, Danila ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Cytoplasmic Trop 1 Ep CAM; Node positive; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; EPITHELIAL CELL ADHESION MOLECULE; TAMOXIFEN;

AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; EVENT FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ITALY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870445093     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys159     Document Type: Article

References (38)

1. Calabrese G, Crescenzi C, Morizio E, Palka G, Guerra E, Alberti S. Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenet Cell Genet 2001;92:164-5.
2. Ripani E, Sacchetti A, Corda D, Alberti S. The human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998;76: 671-6.
3. Klein CE, Hartmann B, Schön MP, Weber L, Alberti S. Expression of 38-kD cell-surface glycoprotein in transformed human keratinocyte cell lines, basal cell carcinomas, and epithelial germs. J Invest Dermatol 1990;95:74-82.
4. Schön MP, Schön M, Mattes MJ, et al. Biochemical and immunological characterization of the human carcinoma-associated antigen MH 99/KS 1/4. Int J Cancer 1993;55:988-95.
5. Zanna P, Trerotola M, Vacca G, et al. Trop-1 is a novel cell growth stimulatory molecule that marks early stages of tumor progression. Cancer 2007;110:452-64.
6. MacDougall JR, Matrisian LM. Targets of extinction: identification of genes whose expression is repressed as a consequence of somatic fusion between cells representing basal and luminal mammary epithelial phenotypes. J Cell Sci 2000;113:409-23.
7. Gosens MJ, Van Kempen LCL, Van de Velde CJH, Van Krieken JHJM, Nagtegaal ID. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 2007;20:221-32.
8. Yanamoto S, Kawasaki G, Yoshitomi I, Iwamoto T, Hirata K, Mizuno A. Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol 2007;43:869-77.
9. Went PT, Lugli A, Meier S, et al. Frequent EpCAM protein expression in human carcinomas. Hum Pathol 2004;35:122-8.
10. Went P, Dirnhofer S, Schöpf D, Moch H, Spizzo G. Expression and prognostic significance of EpCAM. J Cancer Mol 2008;3:169-74.
11. Gastl G, Spizzo G, Obrist P, Dünser M, Mikuz G. Ep-CAM over-expression in breast cancer as a predictor of survival. Lancet 2000;356:1981-2.
12. Schmidt M, Hasenclever D, Schaeffer M, et al. Prognostic effect of epithelial cell adhesion molecule over-expression in untreated node-negative breast cancer. Clin Cancer Res 2008;14:5849-55.
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8.
14. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
15. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979;76:1438-42.
16. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-94.
17. Haisma HJ, Pinedo HM, Rijswijk A, et al. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther 1999;6:1469-74.
18. Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-24.
19. Schmidt M, Scheulen ME, Dittrich C, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 2010;21:275-82.
20. Balzar M, Briaire-De Bruijn IH, Rees-Bakker H, et al. Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions. Mol Cell Biol 2001;21:2570-80.
21. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics subcommitee of the NCI-EORTC working group on cancer diagnostics. Reporting recommendations for tumour marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
22. Spizzo G, Obrist P, Ensinger C, et al. Prognostic significance of Ep-CAM and Her-2/neu over-expression in invasive breast cancer. Int J Cancer 2002;98:883-8.
23. Spizzo G, Went P, Dirnhofer S, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004;86:207-13.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2011, ISBN 3-900051-07-0, URL. http://www.R-project.org/.
25. Greenacre M. Correspondence Analysis in Practice, 2nd edn. London: Chapman & Hall/CRC, 2007.
26. Schoenfeld D. Partial residuals for the proportional hazard regression model. Biometrica 1982;69:239-41.
27. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Clin Trials 1996;17:343-6.
28. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulated cell-cell interactions mediated by classic cadherins. J Cell Biol 1997;139:1337-48.
29. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004;23:5748-58.
30. Tandon AK, Clark GM, Chamness GC, McGuire WL. Association of the 323/A3 surface glycoprotein with tumour characteristics and behaviour in human breast cancer. Cancer Res 1990;50:3317-21.
31. Winter MJ, Nagelkerken B, Mertens AE, Rees-Bakker HA, Briaire-de Bruijn IH, Litvinov SV. Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Exp Cell Res 2003;285:50-8.
32. Winter MJ, Cirulli V, Briaire-de Bruijn IH, Litvinov SV. Cadherins are regulated by Ep-CAM via phosphaditylinositol-3 kinase. Mol Cell Biochem 2007;302:19-26.
33. Bilder D, Perrimon N. Localization of apical epithelial determinants by the basolateral PDZ protein Scribble. Nature 2000;403:676-80.
34. Albertson R, Chabu C, Sheehan A, Doe CQ. Scribble protein domain mapping reveals a multistep localization mechanism and domains necessary for establishing cortical polarity. J Cell Sci 2005;117:6061-70.
35. Grifoni D, Garoia F, Bellosta P, et al. aPKC cortical loading is associated with Lgl cytoplasmic release and tumor growth in Drosophila and human epithelia. Oncogene 2007;26:5960-5.
36. Gardiol D, Zacchi A, Petrera F, Stanta G, Banks L. Human discs large and scrib are localized at the same regions in colon mucosa and changes in their expression patterns are correlated with loss of tissue architecture during malignant progression. Int J Cancer 2006;119:1285-90.
37. Zhan L, Rosenberg A, Bergami KC, et al. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 2008;135:865-78.
38. Lisovsky M, Dresser K, Baker S, et al. Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol 2009;22: 977-84.